Israeli-American AEYE Health wins Prix Galien Award for new AI technology helping prevent blindness
Gary Lloyd |
Nov 06,26 | 01:42 EST
AEYE Health's AEYE-DS technology, designed to prevent blindness with a fully autonomous AI diagnostic tool, has received the prestigious 2026 Prix Galien USA Award for Best Digital Health Solution, recognizing it as one of the most significant distinctions in healthcare innovation. Dr. Zack Dvey-Aharon, Co-founder and CEO of AEYE Health, an Israeli-American digital health company, conceptualized and developed the AEYE-DS system. Its primary objective is to render sight-saving diabetic eye exams widely accessible at virtually any point of care, thereby addressing a critical healthcare need. Diabetic retinopathy, a severe complication associated with diabetes that directly impacts the eyes, is currently identified as the leading cause of blindness among working-age adults. This condition results from damage to the intricate blood vessels within the retina at the back of the eyes. Initially, it may manifest with no discernible symptoms or only very subtle visual disturbances. However, if this condition is left undiagnosed and untreated, it progresses inevitably towards blindness. A significant portion of vision loss attributable to diabetic retinopathy is, in fact, preventable through timely early detection and prompt intervention. Historically, this prevention has necessitated screening by an eye specialist, a requirement that AEYE Health notes creates a substantial barrier to effective patient care. Factors such as limited availability of specialists, extended waiting times for appointments, the financial cost of examinations, and general inconvenience collectively contribute to delayed detection, ultimately culminating in avoidable vision loss. In response to these challenges, AEYE-DS leverages portable and tabletop retinal cameras to conduct a comprehensive diabetic eye examination. This is performed using an FDA-cleared, fully AI-powered diagnostic program that is capable of delivering accurate and almost instantaneous results, crucially without the immediate requirement for physician interpretation.
AEYE expanding across US, developing next-gen platform Following rigorous validation through three prospective, controlled pivotal phase-III clinical trials, the AEYE-DS technology is currently in a phase of rapid expansion across the United States. Dr. Dvey-Aharon articulated that while being honored with the Prix Galien Award represented one of "the greatest honors of my professional life" and served as an "extraordinary recognition of the work of the AEYE Health team," their most profound achievement remains "every patient whose sight can be preserved because this technology exists." He further expressed a forward-looking perspective on the capabilities of artificial intelligence in healthcare, stating, "We are only at the beginning of what autonomous AI can accomplish for global healthcare." In a continuous effort to innovate, AEYE Health is now actively engaged in the development of AEYE-X, which is envisioned as a next-generation platform. This new platform is being designed to facilitate a much broader range of health assessments derived from retinal images. AEYE-X is projected to be capable of assessing more than 100 distinct health indications, which signifies a substantial expansion of the role of retinal imaging far beyond its conventional applications in traditional eye care, as communicated by the company.
AEYE expanding across US, developing next-gen platform
Following rigorous validation through three prospective, controlled pivotal phase-III clinical trials, the AEYE-DS technology is currently in a phase of rapid expansion across the United States. Dr. Dvey-Aharon articulated that while being honored with the Prix Galien Award represented one of "the greatest honors of my professional life" and served as an "extraordinary recognition of the work of the AEYE Health team," their most profound achievement remains "every patient whose sight can be preserved because this technology exists." He further expressed a forward-looking perspective on the capabilities of artificial intelligence in healthcare, stating, "We are only at the beginning of what autonomous AI can accomplish for global healthcare." In a continuous effort to innovate, AEYE Health is now actively engaged in the development of AEYE-X, which is envisioned as a next-generation platform. This new platform is being designed to facilitate a much broader range of health assessments derived from retinal images. AEYE-X is projected to be capable of assessing more than 100 distinct health indications, which signifies a substantial expansion of the role of retinal imaging far beyond its conventional applications in traditional eye care, as communicated by the company.
Read More
